SaraAHurvitzMD

Oncology • Seattle, WA

Professor of Medicine, University of California Los Angeles David Geffen SOM

Join to view full profile

Dr. Hurvitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hurvitz's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-520-5000

Fax+1 310-998-4747

Summary

Dr. Sara Hurvitz is an oncologist in Santa Monica, CA and is affiliated with UCLA Medical Center-Santa Monica. She received her medical degree from University of Southern California School of Medicine, did her residency training in internal medicine at UCLA, served as Chief Resident of Internal Medicine and then completed her hematology/oncology fellowship at UCLA. She has been in practice as a breast cancer medical oncologist since 2006. She has more than 100 publications and over 500 citings.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999

Certifications & Licensure

WA State Medical License 2023 - 2026
CA State Medical License 2001 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com

Clinical Trials

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer Start of enrollment: 2005 May 01
Completed
Phase 2
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
Withdrawn
Phase 1
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 Apr 01
Completed
Phase 2
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients Start of enrollment: 2010 May 01
Completed
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis Start of enrollment: 2013 Jun 26
Completed
Phase 1, Phase 2
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Start of enrollment: 2014 Jun 27
Completed
Phase 1
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 2
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Start of enrollment: 2017 Aug 02
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

62 citations
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
Sara A. Hurvitz, Richard J. Pietras
Cancer. 2008-11-01
554 citations
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni
The New England Journal of Medicine. 2019-06-04
554 citations
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia
The Lancet. Oncology. 2018-07-01

Journal Articles

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Hope S Rugo, Sara A Hurvitz, Lida A Mina, The New England Journal of Medicine
Quality of Life with Talazoparib Versus Physician’s Choice of Chemotherapy in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutation: Patient-Reported Outc...
Sara Hurvitz, MD, Annals of Oncology

Lectures

Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive br...
2019 ASCO Annual Meeting - 6/1/2019
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2âˆ’ advanced breast cancer (ABC) treated with endocrine therapy Â± ribociclib: Overall survival (OS)...
2019 ASCO Annual Meeting - 6/1/2019
Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) adv...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
No Advantage to Dual HER2-Blockade in HER2-Positive Breast Cancer
2013 International Symposium, San Antonio, Texas, USA
No Advantage to Dual HER2-Blockade in HER2-Positive Breast Cancer
San Antonio Breast Cancer Symposium, 2013 International Symposium, San Antonio, Texas, USA
Join now to see all

Authored Content

Buparlisib plus Fulvestrant Versus Placebo plus Fulvestrant for Postmenopausal, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer: Overall Survival Results from BELLE-2October 2018

Press Mentions

Briacell Reports Positive Overall Survival (Os) in Metastatic Breast CancerSeptember 11th, 2024
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast CancerSeptember 11th, 2024
1 NCCN Guidelines for Patients® Inflammatory Breast Cancer, 2023March 23rd, 2023
Join now to see all